Curewell Capital Majority Recapitalizes AMR (Alliance for Multispecialty Research)
March 18, 2022
Alliance for Multispecialty Research (AMR) announced a majority recapitalization led by Curewell Capital, in partnership with existing shareholders and management. The deal is intended to bring new capital and resources to help AMR accelerate growth and expand its footprint for Phase I–IV clinical trial site management.
- Buyers
- Curewell Capital
- Targets
- Alliance for Multispecialty Research (AMR)
- Industry
- Healthcare Services
- Location
- Tennessee, United States
- Transaction Type
- Recapitalization
Explore More
Related Acquisitions
-
AMR Clinical Acquires ClinOhio Research Services
June 29, 2026
Healthcare Services
AMR Clinical (AMR), an integrated multi-site clinical research company, acquired ClinOhio Research Services, a multi-therapeutic clinical research site based in Columbus, Ohio. The acquisition expands AMR’s geographic presence and strengthens capabilities in Dermatology, Women’s Health, and Gastroenterology.
-
Curewell Capital Majority Investment in Wilmington PharmaTech
October 21, 2025
Pharmaceuticals
Los Angeles-based private equity firm Curewell Capital has made a majority investment in Wilmington PharmaTech (WPT), a U.S.-based specialty CRDMO focused on small-molecule API development and manufacturing. Founder and CEO Hui-Yin "Harry" Li will retain a significant ownership stake and remain as CEO; the capital will be used to expand WPT's U.S. manufacturing capacity, including HPAPI suites, and scale end-to-end API development and manufacturing capabilities.
-
Alliance for Multispecialty Research (AMR) Acquires Affinity Health
December 15, 2023
Healthcare Services
Alliance for Multispecialty Research (AMR) has acquired Affinity Health, a clinical research services provider founded in 2015. The deal adds Affinity's sites and eight principal investigators to AMR's network, expanding AMR's geographic footprint (including Chicago and Nashville) and strengthening its clinical trial capabilities and patient diversity.
-
Ampersand Capital Partners Majority Recapitalizes Julius Clinical Research
November 28, 2023
Healthcare Services
Ampersand Capital Partners has completed a majority recapitalization of Julius Clinical Research, a Zeist-based clinical CRO, to support geographic expansion and deepen the company's scientific and therapeutic expertise. The investment will help Julius grow its CRO services in CNS, renal, cardiometabolic and infectious disease areas and expand its footprint in Europe and North America.
-
Cimarron Healthcare Capital Majority Recapitalizes Infusion Management
September 10, 2022
Healthcare Services
Cimarron Healthcare Capital completed a majority recapitalization and growth equity investment in Infusion Management, the MSO affiliated with Infusion for Health. The investment will support Infusion Management's expansion from the greater Los Angeles market across the West Coast and strengthen clinical and management capabilities.
-
Cimarron Healthcare Capital, RAF Industries and Leavitt Equity Partners Recapitalize Advanced Medical Pricing Solutions (AMPS)
May 10, 2022
Healthcare Services
Cimarron Healthcare Capital led an investor group including RAF Industries and Leavitt Equity Partners in a recapitalization of Advanced Medical Pricing Solutions (AMPS) to support the company's growth and expansion. Debt financing was provided by Oxford Finance and Webster Bank, financial terms were not disclosed, and AMPS's original shareholders and management will retain significant ownership and remain in place.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.